Wellness & GLP-1 referral market

A growing weight-loss market is creating a new conversation about facial recovery.

Patients using GLP-1 medications—including Ozempic®, Wegovy®, Mounjaro®, and Zepbound®—may seek support for facial hollowing, reduced soft-tissue volume, and a perceived loss of tone following rapid weight loss.

Often called “Ozempic face,” these visible changes can reflect the loss of facial fat and soft-tissue volume as body weight declines. ISO Metrik does not replace lost facial volume. It gives qualified providers a structured pathway for facial muscle conditioning, motor control, and measurable neuromuscular rehabilitation.

Weight-loss clinician discussing facial changes with a patient
01Weight-loss providers identify the need

Medical weight-loss, obesity medicine, endocrinology, and primary-care practices encounter patients concerned about facial changes during treatment.

Aesthetic clinician discussing facial changes and rehabilitation options with a patient
02Aesthetic providers expand the conversation

Plastic surgeons, dermatologists, and medical spas can distinguish volume-restoration options from facial muscle rehabilitation.

Physical therapist evaluating a patient's facial motor control
03Therapy clinics receive qualified referrals

Participating partners direct appropriate patients to ISO Metrik PT and SLP providers for evaluation and provider-directed treatment.

Emerging referral channelWellness concern → clinical screening → therapy evaluation → measurable program
01IdentifyWeight-loss or wellness partner
02ReferAppropriate PT or SLP clinic
03EvaluateBaseline function and goals
04TreatProgressive resistance pathway